10-Q: ProKidney Advances Kidney Disease Therapy

ProKidney reports positive Phase 2 trial results for rilparencel and secures FDA clarity for its pivotal Phase 3 study, extending cash runway into mid-2027.

Summary

• Reported a net loss attributable to Class A common stockholders of $16.552 million for the three months ended June 30, 2025, compared to $12.506 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $33.286 million, up from $21.998 million in the prior year period.
• Operating loss improved to $39.709 million for Q2 2025 from $43.056 million in Q2 2024, and to $81.097 million for H1 2025 from $83.132 million in H1 2024.
• Research and development expenses decreased by $3.5 million for Q2 2025 and $3.5 million for H1 2025, primarily due to completed/terminated clinical trials, partially offset by increased costs for the ongoing Phase 3 PROACT 1 trial.
• Cash and cash equivalents stood at $84.940 million as of June 30, 2025, down from $99.120 million at December 31, 2024.
• Marketable securities decreased to $209.788 million from $259.172 million over the same period.
• Net cash used in operating activities improved to $61.008 million for the six months ended June 30, 2025, from $72.939 million in the prior year period.
• Completed the REGEN-007 Phase 2 trial, with Group 1 showing a statistically significant 78% improvement in annual eGFR slope (from -5.8 to -1.3 mL/min/1.73m2/year).
• FDA confirmed eGFR slope as a surrogate endpoint for accelerated approval of rilparencel in the ongoing Phase 3 PROACT 1 study, with an acceptable efficacy demonstration of at least 1.5 mL/min/1.73m2/year improvement.
• Completed domestication from the Cayman Islands to Delaware effective July 1, 2025, along with a corporate restructuring.

Sentiment

Score: 8

Explanation: The positive and statistically significant Phase 2 clinical trial results for rilparencel, coupled with clear FDA guidance on the accelerated approval pathway for the pivotal Phase 3 study, represent a significant de-risking event and strong clinical validation. While the company continues to incur losses and will require future capital, this is typical for a clinical-stage biotech with a promising late-stage asset. The clinical progress outweighs the expected financial burn for a growth-oriented investor.

Positives

• REGEN-007 Phase 2 trial Group 1 demonstrated a statistically significant and clinically meaningful 78% improvement in annual eGFR slope, from -5.8 to -1.3 mL/min/1.73m2/year (a 4.6 mL/min/1.73m2/year difference).
• FDA confirmed eGFR slope as an acceptable surrogate endpoint for accelerated approval of rilparencel in the ongoing Phase 3 PROACT 1 study, requiring an effect size of at least 1.5 mL/min/1.73m2/year improvement.
• Nearly half of the patients required for the accelerated approval analysis in the PROACT 1 study have been enrolled.
• The safety profile of rilparencel in REGEN-007 was consistent with previous studies, with no rilparencel-related serious adverse events observed.
• Operating loss improved by $3.347 million for the three months ended June 30, 2025, and by $2.035 million for the six months ended June 30, 2025, compared to the prior year periods.
• Net cash used in operating activities decreased by $11.931 million for the six months ended June 30, 2025, indicating improved operational cash efficiency.
• The company's existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements into mid-2027.

Negatives

• Net loss attributable to Class A common stockholders increased to $16.552 million for Q2 2025 from $12.506 million for Q2 2024, and to $33.286 million for H1 2025 from $21.998 million for H1 2024.
• Cash and cash equivalents decreased from $99.120 million at December 31, 2024, to $84.940 million at June 30, 2025.
• Marketable securities decreased from $259.172 million at December 31, 2024, to $209.788 million at June 30, 2025.
• Interest income decreased by $0.9 million for Q2 2025 and $1.8 million for H1 2025, primarily due to lower investment balances and interest rates.
• The REGEN-007 Phase 2 trial Group 2 (exploratory dosing) showed a 50% improvement in eGFR slope (1.7 mL/min/1.73m2/year difference), but this was not statistically significant (p=0.085).
• The company has not generated any revenue from product sales since its inception and does not expect to in the near future, if at all.
• Substantial additional funding will be needed to support continuing operations and growth strategy, with potential for stockholder dilution from equity raises.

Risks

• The successful development and commercialization of rilparencel and any future product candidates are highly uncertain, with no guarantee of obtaining marketing approval or achieving commercial success.
• The company is unable to predict the nature, timing, and estimated costs to complete development and commercialization of product candidates.
• Significant additional financial resources and time would be required if regulatory authorities demand additional clinical trials or if there are significant delays in current trials.
• Ability to raise additional funds may be adversely impacted by worsening global economic conditions and volatility in financial markets.
• Raising capital through equity or convertible debt securities could dilute existing stockholders' ownership interest.
• Debt financing and equity financing agreements may include covenants limiting the company's ability to incur additional debt, make capital expenditures, or declare dividends.
• If unable to obtain additional funding, the company may be forced to delay, reduce, or eliminate research and development programs, product portfolio expansion, or commercialization efforts, or may be unable to continue operations.
• Raising funds through strategic collaborations may require relinquishing valuable rights to technology, future revenue streams, or product candidates.

Future Outlook

ProKidney anticipates topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval of rilparencel in the second quarter of 2027. The ongoing Phase 3 PROACT 1 study is expected to serve as the confirmatory study for full approval, with updated guidance on its readout timing to be provided in the first half of 2026. The company expects its current cash, cash equivalents, and marketable securities to fund operations into mid-2027, but acknowledges the need for substantial additional funding to support increasing R&D expenses, potential manufacturing costs, and commercialization efforts.

Management Comments

• "We anticipate topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in the second quarter of 2027."
• "We have enrolled nearly half of the patients required for the accelerated approval analysis."
• "The FDA also confirmed that the ongoing Phase 3 PROACT 1 study may serve as the confirmatory study to support full approval of rilparencel based on the primary time-to-event composite endpoint specified in the protocol."
• "Updated guidance on the expected timing of the confirmatory readout will be provided in the first half of 2026."
• "No rilparencel-related serious adverse events were observed across all patients in the study who received at least one rilparencel injection (n=49). The safety profile was consistent with previously reported study results and comparable to a kidney biopsy."
• "We expect that our existing cash, cash equivalents and marketable securities held at June 30, 2025, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027."
• "We expect our expenses to increase substantially if, and as, we: initiate and continue research and clinical development of our product candidates, incur third-party manufacturing costs, seek to identify and develop additional product candidates, make investments in developing internal manufacturing capabilities; and seek regulatory and marketing approvals for our product candidates."

Industry Context

ProKidney operates in the highly innovative but capital-intensive clinical-stage biotechnology sector, specifically targeting chronic kidney disease (CKD) with a novel cell therapy, rilparencel. The RMAT designation from the FDA highlights the potential for accelerated development given the unmet medical need in CKD. The positive Phase 2 results for REGEN-007, particularly the significant eGFR slope improvement in Group 1, position rilparencel favorably against standard-of-care therapies that often only slow disease progression. The FDA's agreement on eGFR slope as a surrogate endpoint for accelerated approval is a critical de-risking event, potentially allowing earlier market entry compared to traditional endpoints. The company's financial situation, characterized by significant R&D expenses and reliance on capital raises, is typical for a biotech at this stage, where substantial investment is required before potential product commercialization.

Comparison to Industry Standards

• The 78% improvement in annual eGFR slope (4.6 mL/min/1.73m2/year difference) observed in REGEN-007 Group 1 significantly exceeds the FDA's acceptable efficacy demonstration of at least 1.5 mL/min/1.73m2/year improvement for accelerated approval in the PROACT 1 study. This suggests a strong clinical signal compared to the regulatory benchmark.
• Standard-of-care therapies for CKD, such as SGLT2 inhibitors (e.g., Farxiga by AstraZeneca, Jardiance by Eli Lilly/Boehringer Ingelheim) and ACE inhibitors/ARBs (e.g., Lisinopril, Losartan), typically aim to slow eGFR decline, often by 1-2 mL/min/1.73m2/year or less. Rilparencel's observed 4.6 mL/min/1.73m2/year improvement in Group 1 of REGEN-007, if replicated in Phase 3, would represent a substantial advancement over current treatments.
• The safety profile of rilparencel, consistent with a kidney biopsy and without rilparencel-related serious adverse events, is a positive indicator for a cell therapy, which often face higher safety scrutiny compared to small molecule drugs.
• The company's cash runway into mid-2027, while requiring future capital raises, is within the typical range for clinical-stage biotechs advancing a late-stage asset, though it is shorter than some larger, more diversified pharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Exchange Agreement: Allows holders of Post-Combination ProKidney Common Units and Class B common stock to exchange them for Class A common stock (one-for-one) or cash, at the company's option.
• Lock-Up Agreement: Imposes transfer restrictions on certain shares held by SCS Sponsor III LLC and Closing ProKidney Unitholders, with various expiration triggers including stock price thresholds ($12.50, $15.00, $20.00, $25.00) and regulatory market authorization for rilparencel.
• Tax Receivable Agreement: Obligates the company to pay Closing ProKidney Unitholders 85% of certain tax savings realized from increases in tax basis due to unit exchanges and other tax attributes.
• Earnout Rights: 17,500,000 Earnout Restricted Common Units and 17,500,000 Earnout Restricted Stock Rights issued to certain stockholders, vesting upon Class A common stock reaching $15.00, $20.00, and $25.00 per share within five years of closing, or upon a change of control at those thresholds.
• Consulting Services Agreement with Nefro Health: ProKidney-KY and ProKidney-US pay Nefro Health (controlled by director Mr. Pablo Legorreta) $25,000 per quarter for R&D and pre-commercialization consulting services. Total payments of $50,000 for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for significant upside if rilparencel achieves accelerated approval and commercial success, driven by strong Phase 2 data and FDA clarity. However, face dilution risk from future equity capital raises and ongoing operating losses.
• Employees: Continued employment under new agreements for key executives, indicating stability in leadership. Equity-based compensation plans are in place, aligning employee incentives with company performance.
• Customers (future): Potential for a novel cell therapy to preserve kidney function and delay/eliminate dialysis/transplantation, offering a significant new treatment option for patients with chronic kidney disease.
• Creditors: The company's liquidity position, while decreasing, is projected to last into mid-2027, providing some financial stability in the near term, but long-term viability depends on successful product development and further funding.
• Regulatory Authorities (FDA): The company is actively engaging with the FDA, securing agreement on a surrogate endpoint for accelerated approval, which demonstrates a collaborative and compliant approach to drug development.

Next Steps

• Continue enrollment and activities for the Phase 3 PROACT 1 trial.
• Anticipate topline data readout of eGFR slope from PROACT 1 for accelerated approval in Q2 2027.
• Provide updated guidance on the expected timing of the confirmatory readout for PROACT 1 in 1H 2026.
• Submit full results from the REGEN-007 Phase 2 trial to the American Society of Nephrology (ASN) 2025 Kidney Week as a late-breaking clinical trial.
• Assess the effect of the 'One Big Beautiful Bill Act' on consolidated financial statements, with reflection expected to begin in the three-month period ended September 30, 2025.
• Potentially raise additional capital through the new $200 million at-the-market equity offering.

Key Dates

Recommendation

The positive Phase 2 REGEN-007 trial results, particularly the statistically significant eGFR improvement in Group 1, provide strong clinical validation for rilparencel. The FDA's confirmation of eGFR slope as a surrogate endpoint for accelerated approval in the Phase 3 PROACT 1 study significantly de-risks the regulatory pathway and could lead to earlier market entry. While the company is pre-revenue and will require substantial future funding, which carries dilution risk, the clinical advancements and regulatory clarity are highly favorable for a clinical-stage biotech. For investors with a higher risk tolerance seeking exposure to innovative therapies for unmet medical needs, the potential upside from successful clinical development and accelerated approval warrants a 'buy' recommendation, despite the ongoing cash burn.

Keywords

Chronic Kidney Disease, CKD, Rilparencel, REACT, Cell Therapy, Biotechnology, Clinical Stage, Phase 3 Trial, PROACT 1, REGEN-007, eGFR, FDA Accelerated Approval, Biologics License Application, BLA, Autologous Cell Therapy, Renal, Type 2 Diabetes, Albuminuria, SEC Filing, 10-Q